Recently, the highly selective JAK1 inhibitor golicitinib (trade name: Goraize) has been officially approved by the National Medical Products Administration (NMPA) for the treatment of relapsed and refractory peripheral T-cell lymphoma (r/r PTCL). Goraize is the second global first-in-class/potential first-in-class innovative drug successfully launched by Dezima Pharmaceuticals within one year. Zhang Xiaolin, founder, chairman and CEO of Dezima Pharmaceuticals, said: "With its new mechanism of action, Goraize can effectively treat all subtypes of PTCL, filling the gaps in the treatment of multiple subtypes by previous drugs. The approval of Goraize in China allows Chinese patients to benefit from the"global first-in-class" innovative therapy first."
戈利昔替尼获批！迪哲医药董事长：中国患者率先受益于“全球首创”创新疗法
Golixetinib has been approved! Di Zhe Pharmaceutical's director: Chinese patients are the first to benefit from the "global first" innovative therapy.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.